Reducing irinotecan‐associated diarrhea in children

Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan. Pediatr Blood Cancer 2008; 50:201–207. © 2007 Wiley‐Liss, Inc.

[1]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[2]  B. Geoerger,et al.  Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Verweij,et al.  Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. , 2006, The oncologist.

[5]  J. Panetta,et al.  UGT1A1 promoter genotype correlates with pharmacokinetics but not toxicity in patients receiving protracted irinotecan (IRN). , 2006, Journal of Clinical Oncology.

[6]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Rocchi,et al.  Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan‐based chemotherapy , 2006, Cancer.

[8]  G. Brandi,et al.  Intestinal microflora and digestive toxicity of irinotecan in mice. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  P. Houghton,et al.  Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Carli,et al.  Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma , 2006, Cancer.

[11]  P. Beale,et al.  A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer , 2006, Cancer Chemotherapy and Pharmacology.

[12]  T. Kamataki,et al.  Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea , 2006, Cancer Chemotherapy and Pharmacology.

[13]  J. Kuttesch,et al.  A phase I study of irinotecan administered on a weekly schedule in pediatric patients , 2006, Pediatric blood & cancer.

[14]  N. Vasudev,et al.  Intravenous irinotecan plus oral ciclosporin. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  K. Kobayashi,et al.  A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer , 2005, British Journal of Cancer.

[16]  J. Bowen,et al.  Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor‐bearing DA rats , 2005, International journal of cancer.

[17]  H. Messmann,et al.  Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer , 2005, Oncology.

[18]  J. Sussman,et al.  The Crystal Structure of the Complex of the Anticancer Prodrug 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica Acetylcholinesterase Provides a Molecular Explanation for Its Cholinergic Action , 2005, Molecular Pharmacology.

[19]  M. Ratain,et al.  Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer , 2005, Cancer Chemotherapy and Pharmacology.

[20]  H. Bouzourène,et al.  Irinotecan-induced Colitis , 2005, International journal of surgical pathology.

[21]  N. Cheung,et al.  Five‐day courses of irinotecan as palliative therapy for patients with neuroblastoma , 2005, Cancer.

[22]  N. Meropol,et al.  UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  A. Friedman,et al.  Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma , 2005, Cancer.

[24]  A. Oza,et al.  Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Vecchione,et al.  New approaches to prevent intestinal toxicity of irinotecan-based regimens. , 2004, Cancer treatment reviews.

[26]  D. Richel,et al.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[27]  S. Rosenoff.  Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. , 2004, European journal of cancer care.

[28]  T. Murakami,et al.  Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients. , 2004, Oncology reports.

[29]  E. Thiel,et al.  Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[31]  M. Baiget,et al.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[32]  J. Ajani,et al.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Buelow,et al.  Oral RDP58 Allows CPT-11 Dose Intensification for Enhanced Tumor Response by Decreasing Gastrointestinal Toxicity , 2004, Clinical Cancer Research.

[35]  P. Houghton,et al.  Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors , 2004, Clinical Cancer Research.

[36]  F. Lévi,et al.  Circadian Rhythm of Irinotecan Tolerability in Mice , 2004, Chronobiology international.

[37]  D. Frappaz,et al.  A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Vecchione,et al.  Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Y. Cheung,et al.  The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents. , 2003, Oncology reports.

[40]  K. Mori,et al.  Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer , 2003, Cancer Chemotherapy and Pharmacology.

[41]  G. Hall,et al.  Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Levine,et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. , 2002, Cancer research.

[43]  Y. Sugiyama,et al.  Reduced Gastrointestinal Toxicity Following Inhibition of the Biliary Excretion of Irinotecan and Its Metabolites by Probenecid in Rats , 2002, Pharmaceutical Research.

[44]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[45]  J. Hecht,et al.  Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma , 2002, Cancer.

[46]  I. Cameron,et al.  Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice , 2002, British Journal of Cancer.

[47]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  W. Gerald,et al.  Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience , 2002, Journal of pediatric hematology/oncology.

[49]  G. Koumakis,et al.  Control of irinotecan-induced diarrhea by octreotide after loperamide failure , 2001, Supportive Care in Cancer.

[50]  J. Verweij,et al.  Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  P. Halushka,et al.  Disposition and metabolism of the flavonoid chrysin in normal volunteers. , 2001, British journal of clinical pharmacology.

[52]  R. Goldberg,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[53]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[54]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[55]  P. Houghton,et al.  Clinical use of topoisomerase I inhibitors in anticancer treatment. , 2000, Medical and pediatric oncology.

[56]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[57]  C. Morton,et al.  Proficient metabolism of irinotecan by a human intestinal carboxylesterase. , 2000, Cancer research.

[58]  M. Hauer-Jensen,et al.  Effect of thalidomide on gastrointestinal toxic effects of irinotecan , 2000, The Lancet.

[59]  M. Ychou,et al.  Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. , 2000, American journal of clinical oncology.

[60]  S. Kudoh,et al.  pH‐dependent uptake of irinotecan and its active metabolite, SN‐38, by intestinal cells , 1999, International journal of cancer.

[61]  T. Loeffler,et al.  Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  C. Bucana,et al.  Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  M. Ciotti,et al.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. , 1999, Biochemical and biophysical research communications.

[64]  P. Houghton,et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[66]  Y. Sugiyama,et al.  Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. , 1998, Cancer research.

[67]  P. Houghton,et al.  Animal models for studying the action of topoisomerase I targeted drugs. , 1998, Biochimica et biophysica acta.

[68]  J. Black,et al.  Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. , 1998, Cancer research.

[69]  J. Hecht.  Gastrointestinal toxicity or irinotecan. , 1998, Oncology.

[70]  G. Vassal,et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[72]  T Ishizaki,et al.  Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[73]  T. Kamataki,et al.  Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. , 1997, Japanese journal of pharmacology.

[74]  A. Ikari,et al.  Thromboxane A2, released by the anti‐ tumour drug irinotecan, is a novel stimulator of Cl− secretion in isolated rat colon , 1997, The Journal of physiology.

[75]  T. Hodge,et al.  Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. , 1996, Journal of the National Cancer Institute.

[76]  S. Kudoh,et al.  Irinotecan (CPT-11): pharmacology and clinical applications. , 1996, Critical reviews in oncology/hematology.

[77]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[78]  G. Vassal,et al.  Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. , 1996, British Journal of Cancer.

[79]  H. Soda,et al.  Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. , 1995, Journal of the National Cancer Institute.

[80]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[81]  P. Houghton,et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. , 1993, Cancer research.

[82]  K. Akahane,et al.  Inhibitory Activity of Camptothecin Derivatives Against Acetylcholinesterase in Dogs and Their Binding Activity to Acetylcholine Receptors in Rats , 1993, The Journal of pharmacy and pharmacology.

[83]  J. Schwartz,et al.  Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. , 1992, Gut.

[84]  T. Mcelwain,et al.  The modification of melphalan toxicity in tumor bearing mice by S‐2‐(3‐aminopropylamino)‐ethylphosphorothioic acid (WR2721) , 1982, American journal of clinical oncology.

[85]  R. Arceci.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group , 2008 .

[86]  P. Houghton,et al.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors , 2004, Cancer Chemotherapy and Pharmacology.

[87]  G. Hall,et al.  Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. , 2003, Journal of Clinical Oncology.

[88]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[89]  D. Amadori,et al.  High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients , 2000, Supportive Care in Cancer.

[90]  D. Savarese,et al.  Glutamine for irinotecan diarrhea. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.